Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A

NCT02083965 is registered in ClinicalTrials.gov with Bioverativ Therapeutics Inc. as lead sponsor.

NCT NCT02083965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02083965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A
Lead sponsor
Bioverativ Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2014
Completion date
May 31, 2015
Enrollment
19 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a